美国慢性血栓栓塞性肺动脉高压登记研究:入组特征与1年随访结果
美国慢性血栓栓塞性肺动脉高压登记(US-CTEPH-R)为多中心、前瞻性、纵向观察性登记,纳入新诊断(<6个月)CTEPH患者,要求右心导管证实平均肺动脉压≥25 mmHg且影像学确认CTEPH。2015至2018年共纳入750例,随访至2019年,每半年一次。87.9%有急性肺栓塞史,诊断延迟中位10个月,入组时多数为WHO功能分级3级,中位平均肺动脉压44 mmHg。接受PTE手术者中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率3.9%;1年时手术组WHO功能分级1-2级比例82.9%,高于不可手术组48.2%和可手术未手术组56%(P<.001)。
要点
- CTEPH诊断延迟常见,中位延迟10个月;入组时多数患者WHO功能分级3级,中位平均肺动脉压44 mmHg。
- PTE手术使中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率为3.9%。
- 1年随访时,手术组WHO功能分级1-2级比例为82.9%,不可手术组为48.2%,可手术未手术组为56%(P<.001)。
- 不可手术患者较手术患者年龄更大、较少肥胖、较少有DVT史、非O型血或易栓症,更常有COPD或癌症史。
- 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。
适用人群与场景
- 新诊断(<6个月)CTEPH患者,右心导管证实平均肺动脉压≥25 mmHg且影像学确认CTEPH。
- 2015至2018年纳入750例,随访至2019年,每半年随访一次。
诊断标准与关键阈值
- 入组标准:右心导管证实平均肺动脉压≥25 mmHg,且影像学确认CTEPH。
- 诊断延迟中位10个月;入组时多数患者WHO功能分级3级,中位平均肺动脉压44 mmHg。
处置流程与药物剂量
- 可手术患者接受肺动脉血栓内膜剥脱术(PTE),中位肺血管阻力从6.9降至2.6 Wood单位(P<.001)。
- 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。
研究设计与关键结果
- 多中心、前瞻性、纵向观察性登记,纳入750例新诊断CTEPH患者,分为手术组(n=566)、可手术未手术组(n=88)和不可手术组(n=96)。
- 87.9%患者有急性肺栓塞史;诊断延迟中位10个月;入组时多数WHO功能分级3级,中位平均肺动脉压44 mmHg。
- 不可手术患者较手术患者年龄更大、较少肥胖、较少有DVT史、非O型血或易栓症,更常有COPD或癌症史。
- PTE术后中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率3.9%。
- 1年随访时,手术组WHO功能分级1-2级比例为82.9%,不可手术组为48.2%,可手术未手术组为56%(P<.001)。
- 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、纵向、观察性登记研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于新诊断CTEPH患者,应评估手术可操作性;接受PTE手术的患者1年WHO功能分级1-2级比例更高(82.9% vs 不可手术组48.2% vs 可手术未手术组56%,P<.001)。
- PTE手术可使中位肺血管阻力从6.9降至2.6 Wood单位(P<.001),院内死亡率为3.9%。
- 1年随访时,手术组接受氧疗、利尿剂或肺动脉高压靶向治疗的比例低于不可手术组。
指南或共识出处
- 美国慢性血栓栓塞性肺动脉高压登记(US-CTEPH-R),ClinicalTrials.gov注册号NCT02429284。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The United States Chronic Thromboembolic Pulmonary Hypertension Registry (US-CTEPH-R) was designed to characterize the demographic characteristics, evaluation, clinical course, and outcomes of surgical and nonsurgical therapies for patients with chronic thromboembolic pulmonary hypertension.
RESEARCH QUESTION: What are the differences in baseline characteristics and 1-year outcomes between operated and nonoperated subjects?
STUDY DESIGN AND METHODS: This study describes a multicenter, prospective, longitudinal, observational registry of patients newly diagnosed (< 6 months) with CTEPH. Inclusion criteria required a mean pulmonary artery pressure ≥ 25 mm Hg documented by right heart catheterization and radiologic confirmation of CTEPH. Between 2015 and 2018, a total of 750 patients were enrolled and followed up biannually until 2019.
RESULTS: Most patients with CTEPH (87.9%) reported a history of acute pulmonary embolism. CTEPH diagnosis delays were frequent (median, 10 months), and most patients reported World Health Organization functional class 3 status at enrollment with a median mean pulmonary artery pressure of 44 mm Hg. The registry cohort was subdivided into Operable patients undergoing pulmonary thromboendarterectomy (PTE) surgery (n = 566), Operable patients who did not undergo surgery (n = 88), and those who were Inoperable (n = 96). Inoperable patients were older than Operated patients; less likely to be obese; have a DVT history, non-type O blood group, or thrombophilia; and more likely to have COPD or a history of cancer. PTE resulted in a median pulmonary vascular resistance decline from 6.9 to 2.6 Wood units (P < .001) with a 3.9% in-hospital mortality. At 1-year follow-up, Operated patients were less likely treated with oxygen, diuretics, or pulmonary hypertension-targeted therapy compared with Inoperable patients. A larger percentage of Operated patients were World Health Organization functional class 1 or 2 at 1 year (82.9%) compared with the Inoperable (48.2%) and Operable/No Surgery (56%) groups (P < .001).
INTERPRETATION: Differences exist in the clinical characteristics between patients who exhibited operable CTEPH and those who were inoperable, with the most favorable 1-year outcomes in those who underwent PTE surgery.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02429284; URL: www.clinicaltrials.gov.
参考来源
- Kerr KM, Elliott CG, Chin K, et al. Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up. Chest. 2021. PMID: 34090871. doi:10.1016/j.chest.2021.05.052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。